58 - Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised,double-blind, placebo controlled, phase 3 study

https://is1-ssl.mzstatic.com/image/thumb/Podcasts112/v4/0c/e4/6b/0ce46b91-3d22-279b-52fe-d3b1a2a47107/mza_11625791986367831883.jpg/600x600bb.jpg

TMO EPM / Hemato H9J

64 episodes

4 days ago

Podcast de discussão de assuntos em Hematologia do Transplante de Medula Óssea da Escola Paulista de Medicina (UNIFESP) e da Hematologia do Hospital 9 de Julho - DASA

Medicine

Health & Fitness

RSS

All content for TMO EPM / Hemato H9J is the property of TMO EPM / Hemato H9J and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Podcast de discussão de assuntos em Hematologia do Transplante de Medula Óssea da Escola Paulista de Medicina (UNIFESP) e da Hematologia do Hospital 9 de Julho - DASA

Medicine

Health & Fitness

https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_episode/38086306/38086306-1750633562867-a49cb57974885.jpg

58 - Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised,double-blind, placebo controlled, phase 3 study

TMO EPM / Hemato H9J

34 minutes

4 months ago

58 - Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised,double-blind, placebo controlled, phase 3 study

Discussão do artigo: "Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo controlled, phase 3 study" de Wang M Lancet Oncology 2025

Apresentado por: Dr. Guilherme Rodrigues

Discussão por: Dr. Eduardo Burlamaqui, Dr. Lucas Salviano, Dr. Pedro Moraes e Dr. Vinícius Molla